Latest Oncology News

Frontline Olaparib Plus Abiraterone Significantly Improves rPFS in mCRPC

September 24, 2021

The phase 3 PROpel clinical trial has achieved its primary end point of improvement in radiographic progression-free survival in men with metastatic castration resistant prostate cancer using the novel combination of olaparib and abiraterone.